// App-Quantinova.ai

P14.01 : Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC

Researchers

Presenter

  • M.D. Hellmann

Principal Investigators

  • Y. Cheng

  • G. De Castro Jr

  • T. Takahashi

  • P. Zhang

  • J.C. Yang

Medical Centers

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Merck & Co., Inc., Kenilworth, NJ

  • Jilin Provincial Cancer Hospital, Changchun, China

  • Oncology, Instituto Do Câncer Do Estado de São Paulo, São Paulo/BR

  • Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

  • Fox Chase Cancer Center, Philadelphia, PA

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • McMaster University Juravinski Cancer Center, Hamilton, ON, Canada

  • Shizuoka Cancer Center, Sunto-Gun, Japan

Locations

  • Taiwan

  • United States

  • United Kingdom

  • China

  • Brazil

  • Turkey

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • P14

  • Anaplastic lymphoma Kinase

  • Proto-oncogene tyrosine-protein kinase ROS

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02964013

  • NCT04738487

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved